[go: up one dir, main page]

DK1051500T3 - Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme - Google Patents

Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme

Info

Publication number
DK1051500T3
DK1051500T3 DK99905450T DK99905450T DK1051500T3 DK 1051500 T3 DK1051500 T3 DK 1051500T3 DK 99905450 T DK99905450 T DK 99905450T DK 99905450 T DK99905450 T DK 99905450T DK 1051500 T3 DK1051500 T3 DK 1051500T3
Authority
DK
Denmark
Prior art keywords
aur1
aur2
polypeptides
diagnosis
treatment
Prior art date
Application number
DK99905450T
Other languages
English (en)
Inventor
Gregory D Plowman
Kevin Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK1051500T3 publication Critical patent/DK1051500T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99905450T 1998-01-22 1999-01-21 Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme DK1051500T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/012,135 US6716575B2 (en) 1995-12-18 1998-01-22 Diagnosis and treatment of AUR1 and/or AUR2 related disorders
PCT/US1999/001283 WO1999037788A2 (en) 1998-01-22 1999-01-21 Diagnosis and treatment of aur1 and/or aur2 related disorders

Publications (1)

Publication Number Publication Date
DK1051500T3 true DK1051500T3 (da) 2005-12-19

Family

ID=21753554

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99905450T DK1051500T3 (da) 1998-01-22 1999-01-21 Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme

Country Status (11)

Country Link
US (3) US6716575B2 (da)
EP (1) EP1051500B1 (da)
JP (1) JP2002508937A (da)
AT (1) ATE302278T1 (da)
AU (1) AU2560599A (da)
CA (1) CA2318352A1 (da)
CY (1) CY1105446T1 (da)
DE (1) DE69926731T2 (da)
DK (1) DK1051500T3 (da)
ES (1) ES2247783T3 (da)
WO (1) WO1999037788A2 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301500A1 (en) 1997-08-27 1999-03-04 Pioneer Hi-Bred International, Inc. Genes encoding enzymes for lignin biosynthesis and uses thereof
WO2000061744A1 (fr) * 1999-04-09 2000-10-19 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux genes de foetus
DE60133897D1 (de) * 2000-06-28 2008-06-19 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105949B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6653301B2 (en) * 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
US20030031655A1 (en) * 2001-02-08 2003-02-13 Sequitur, Inc. Methods of light activated release of ligands from endosomes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
EP1472245A2 (en) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
DE60332604D1 (de) * 2002-03-15 2010-07-01 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
WO2003083096A2 (en) * 2002-03-28 2003-10-09 Qlt Inc. Cancer associated protein kinases and their uses
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ZA200501124B (en) 2002-08-02 2006-10-25 Vertex Pharma Pyrazole compositions useful as inhibitors of GSK-3
SI1546182T1 (sl) * 2002-09-11 2011-04-29 Genentech Inc Sestavki in postopki za diagnozo in zdravljenje tumorja
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
DE60328735D1 (de) 2002-12-24 2009-09-17 Astrazeneca Ab Chinazolinderivate
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP4568716B2 (ja) * 2003-02-20 2010-10-27 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を測定するためのイントロンｒｎａの使用
EP2226396A1 (en) * 2003-05-30 2010-09-08 Genomic Health, Inc. Gene expression markers for response to EGFR inhibitor drugs
EP1641810B2 (en) 2003-06-24 2017-04-19 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
AU2004284434A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR assay system for gene expression profiling
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ES2360113T3 (es) * 2003-12-23 2011-06-01 Genomic Health, Inc. Amplificación universal de rna fragmentado.
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006031273A2 (en) * 2004-06-18 2006-03-23 Cytokinetics, Inc. Cellular phenotype
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
AR051467A1 (es) * 2004-10-29 2007-01-17 Banyu Pharma Co Ltd Derivados de aminopiridina con accion inhibitoria selectiva de la aurora quinasa a
ES2778851T3 (es) * 2004-11-05 2020-08-12 Genomic Health Inc Predicción de la respuesta a la quimioterapia mediante el uso de marcadores de expresión génica
WO2006052731A2 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
US20060142247A1 (en) * 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
WO2006108489A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
EP1885725B1 (en) * 2005-04-14 2008-09-24 F.Hoffmann-La Roche Ag Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
WO2007020853A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
CA2622352C (en) * 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1948193B1 (en) * 2005-11-03 2015-01-07 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2008011769A (es) * 2006-03-20 2008-09-25 Hoffmann La Roche Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
JP2009530337A (ja) * 2006-03-23 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー 置換インダゾール誘導体、その製造方法、及びその薬剤としての利用法
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2008057940A1 (en) * 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
JP2010513567A (ja) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン
EP2137183B1 (en) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AU2008226457B2 (en) * 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
CN101679386A (zh) 2007-04-13 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
WO2008137621A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5572087B2 (ja) * 2007-05-02 2014-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
CA2685876A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
EP2164842A2 (en) * 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2008154026A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CN101790532B (zh) * 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
EP2323622A1 (en) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2065653B (en) 1979-12-19 1983-03-09 Nat Res Dev Anti-cancer quinazoline derivatives
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
WO1992021660A1 (en) 1991-05-29 1992-12-10 Pfizer, Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
EP0654024A1 (en) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
EP0703984A1 (en) 1993-04-07 1996-04-03 Cancer Research Campaign Technology Limited Methods for screening of substances for therapeutic activity and yeast for use therein
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5830648A (en) 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging
EP1655369A1 (en) 1995-12-18 2006-05-10 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders

Also Published As

Publication number Publication date
WO1999037788A2 (en) 1999-07-29
ATE302278T1 (de) 2005-09-15
EP1051500A2 (en) 2000-11-15
AU2560599A (en) 1999-08-09
US6841579B1 (en) 2005-01-11
ES2247783T3 (es) 2006-03-01
WO1999037788A3 (en) 1999-09-30
WO1999037788A9 (en) 1999-11-04
US6716575B2 (en) 2004-04-06
CY1105446T1 (el) 2010-04-28
CA2318352A1 (en) 1999-07-29
US20020081578A1 (en) 2002-06-27
US20050002938A1 (en) 2005-01-06
DE69926731T2 (de) 2006-05-18
EP1051500B1 (en) 2005-08-17
US6207401B1 (en) 2001-03-27
JP2002508937A (ja) 2002-03-26
DE69926731D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DK0528932T3 (da) Protein associeret med akut pancreatitis og midler til diagnose af akut pancreatitis
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
DE69932813D1 (de) Nukleinsäurebindungsproteine
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
DE69833014D1 (de) Menschliche toll homologen
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DE69934324D1 (de) Behandlung von entzündungskrankheiten
DE60034966D1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
ATE265533T1 (de) Saeugetierchemokine
FI885312L (fi) Menetelmä spesifisesti sitovan proteiinin ja vastaavan sidottavan aineen välisen reaktion yhden tai useamman komponentin määrittämiseksi koenäytteestä käyttäen ainakin yhtä leimattua komponenttia, menetelmä leimatun komponentin valmistamiseksi sekä koepakkaus.......
ATE294237T1 (de) S?ugetier thymokingene
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs
DE69940812D1 (de) Mekk1 serin threonin kinasen -fha forkhead verbundenes bereich -interagierendes protein 1 (mif1)
KR880701886A (ko) 췌장효소원의 유리활성화 펩티드의 면역검정에 의한 질병의 진단, 위중도 예견, 및 모니터링
NO20016340L (no) Hodetraumeindusert cytoplasmatisk kalsiumbindende protein
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
WO2000037639A3 (en) Lymphocytic membrane proteins